Category: freely available

ExpungedBob? Algae journal pulls phytoplankton paper with unwitting co-author

Mashup of Chevron-SpongeBob ad courtesy http://www.flickr.com/photos/jonathanmcintosh/

While looking at a recent retraction notice in the Journal of Phycology, the one of us with small children at home couldn’t help but imagine a conversation between cartoon character SpongeBob and his nemesis, Plankton:

SpongeBob: You used me … for land development! That wasn’t nice.

Sheldon J. Plankton: Haven’t you figured it out, SpongeBob? Nice guys finish last. Only aggressive people conquer the world. Ha ha ha ha!

SpongeBob: Well … what about aggressively nice people?

Who knew the world of phytoplankton could be so cutthroat? (Spoiler alert: we did.)

Consider: The Journal of Phycology — phycology is the study of algae and related organisms — is retracting a paper after learning that one of the three co-authors, well, wasn’t. Cyanobacteria may be the oldest known life form on earth, but the hyper-ambitious aren’t far behind.

Here’s the notice: Continue reading ExpungedBob? Algae journal pulls phytoplankton paper with unwitting co-author

Another retraction for Naoki Mori (make that 23?)

The retraction total for Naoki Mori continues to rise.

The October issue of Biochemical and Biophysical Research Communications has retracted a 2007 paper by Mori et al for the same issues — manipulated images — that  brought down the 20-odd other papers of his since the scandal broke in late December.

Here’s the notice for the pulled paper, titled “Downregulation of citrin, a mitochondrial AGC, is associated with apoptosis of hepatocytes:” Continue reading Another retraction for Naoki Mori (make that 23?)

Mistaken notice as Ben Gurion researchers retract vitamin D paper for duplication

“Clare Francis,” a prolific pseudonymous Retraction Watch tipster, emailed us recently to flag a retraction in the Journal of Steroid Biochemistry and Molecular Biology (JSBMB) of “The anti-inflammatory activity of 1,25-dihydroxyvitamin D3 in macrophages,” a paper by Amos Douvdevani and colleagues at Ben Gurion University in Israel.

Here’s what we found when we clicked on the notice for the 2007 paper, which has been cited 32 times, according to Thomson Scientific’s Web of Knowledge:

This article has been retracted at the request of the authors, in response to concerns raised by the research committee at the authors’ institution. The authors stated the committee had given approval but the committee states no approval was given. The research committee has asked the authors to retract the paper and the authors have agreed.

That sounded odd to us, since it was unclear what approval was needed, or hadn’t been given. Continue reading Mistaken notice as Ben Gurion researchers retract vitamin D paper for duplication

“Ill communication” leads to retraction of tissue paper (sorry) for authorship issues

Like many researchers, Frank Walboomers frequently checks the scientific databases to see when his latest publications appear. He was doing so a few months ago when he came across his name on an article — “Effects of pro-inflammatory cytokines on mineralization potential of rat dental pulp stem cells” — published online in July in the Journal of Tissue Engineering and Regenerative Medicine, that he hadn’t written.

The first author of the paper, Xuechao Yang, was a former doctoral student in Walboomers’ laboratory at Radboud University Nijmegen. It didn’t take Walboomers long to figure out what had happened: Continue reading “Ill communication” leads to retraction of tissue paper (sorry) for authorship issues

New in PNAS: Potti retraction number seven, and a Potti correction

The Proceedings of the National Academy of Sciences (PNAS) has published the seventh retraction for former Duke researcher Anil Potti, who now faces a lawsuit in the midst of an ongoing investigation into his work:

Retraction for “A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities,” by Katherine S. Garman, Chaitanya R. Acharya, Elena Edelman, Marian Grade, Jochen Gaedcke, Shivani Sud, William Barry, Anna Mae Diehl, Dawn Provenzale, Geoffrey S. Ginsburg, B. Michael Ghadimi, Thomas Ried, Joseph R. Nevins, Sayan Mukherjee, David Hsu, and Anil Potti, which appeared in issue 49, December 9, 2008, of Proc Natl Acad Sci USA (105:19432–19437; first published December 2, 2008; 10.1073/pnas.0806674105).

The authors wish to note the following: “We wish to retract this article because we have been unable to reproduce certain key experiments described in the paper regarding validation and use of the colon cancer prognostic signature. This includes the validation performed with dataset E-MEXP-1224, as reported in Fig. 2A, as well as the generation of prognostic scores for colon cancer cell lines, as reported in Fig. 4. Because these results are fundamental to the conclusions of the paper, the authors formally retract the paper. We deeply regret the impact of this action on the work of other investigators.”

The 2008 paper, which has been cited 27 times, according to Thomson Scientific’s Web of Knowledge, was already the subject of a minor 2009 correction: Continue reading New in PNAS: Potti retraction number seven, and a Potti correction

Science issues Expression of Concern over already-corrected Melendez-Puneet paper

Two weeks ago, we posted on a Nature Immunology retraction by a group that had earlier published a correction to figures in a Science paper. At the time, many readers suggested there was more to this story — and we had the same hunch.

Turns out those hunches were right.

Today, Science issued an “Expression of Concern” about the paper they’ve already corrected: Continue reading Science issues Expression of Concern over already-corrected Melendez-Puneet paper

You can do that? A massive correction in Nature, but no retraction

courtesy Nature

This past April, Amparo Acker-Palmer and colleagues published a study in Nature, “Ephrin Bs are essential components of the Reelin pathway to regulate neuronal migration.” Within a day of its publication, Nature readers were raising questions about many of its figures. They started like this:

Andy Gu said:

Looks like Fig 1a, the two middle figures are actually the same with little move from desired regions. I don’t trust their data now…..

After several such comments, Nature senior editor Noah Gray weighed in: Continue reading You can do that? A massive correction in Nature, but no retraction

Lack of ethical approval leads to JCO retraction

The Retraction Watch category for “lack of IRB approval” as a reason for retraction — a subject we covered in our most recent Lab Times column — is growing. First there were the 90-odd retractions by Joachim Boldt, then three by Australian researchers studying Aussie-rules football players. Now, we learn that the Journal of Clinical Oncology has retracted a paper over concerns that the authors failed to obtain ethical approval to conduct their study.

The 2010 publication, by researchers at Saitama Medical University in Japan, reported on an analysis of 314 lymphoma patients being treated with chemotherapy — some, and perhaps none, of whom knew they were being studied.

Here’s the notice, which appeared this month: Continue reading Lack of ethical approval leads to JCO retraction

*Savaskan and Nitsch, forced to retract FASEB J paper, correct Cell study with duplicated figure

In August, we wrote about the complicated case of a paper retracted from FASEB Journal that had originally been slated for a correction instead. There had been allegations of misconduct by one of the authors, Nicolai E. Savaskan, and the key parts of the retraction notice for the paper were as follows:

A well-recognized and top-class fact finding commission concluded that the publication contains gross flaws. A key figure (Figure 14) and the conclusions drawn from it could not be underlined with the corresponding primary data.

Savaskan told us at the time that FASEB Journal had agreed to a correction of the figure in question, but ended up retracting the paper after receiving a letter from Annette Gruters-Kieslich at Charite – Universitatsmedizin Berlin, where the work was done. We didn’t get much of an answer from FASEB Journal about why they changed their minds.

*Since understanding why one paper warrants a correction and another gets retracted is important for us at Retraction Watch, a correction of a 2009 Cell paper by a group that included Savaskan and his FASEB J c0-author Robert Nitsch caught our eye. The correction for “Synaptic PRG-1 Modulates Excitatory Transmission via Lipid Phosphate-Mediated Signaling” — a paper cited nine times so far, according to Thomson Scientific’s Web of Knowledge — ran in the September 16, 2011 issue of Cell: Continue reading *Savaskan and Nitsch, forced to retract FASEB J paper, correct Cell study with duplicated figure

More on Hattori case from co-author: Did grudge lead to scientist’s fall?

We have an update on the case of Yoshiyuki Hattori, the Japanese endocrinologist who has had a half-dozen papers retracted because of issues involving reused data. We’ve reported on some of those retractions, and report on three new ones here.

As a trainee, Hattori spent some time in England, where he met Steven Gross, a prominent pharmacology researcher at Cornell. Gross was impressed with the young physician-scientist, and invited him back to his New York City laboratory to do a postdoc.

Gross’ name appears on one of the retracted articles, “NO suppresses while peroxynitrite sustains NF-κB: a paradigm to rationalize cytoprotective and cytotoxic actions attributed to NO,” which appeared in 2004 in the journal Cardiovascular Research and has been cited 42 times, according to Thomson Scientific’s Web of Knowledge.

According to the notice: Continue reading More on Hattori case from co-author: Did grudge lead to scientist’s fall?